ACE2 and COVID-19: Recent evidence demonstrated an increased risk of hypokalemia in hospitalized COVID-19 patients.22 A proposed mechanism involves enhanced ACE2 degradation after binding with SARS-CoV-2; thus, the unopposed RAS axis generates increased potassium loss in infected patients.19 In non-COVID-19 patients, hyperkalemia is not an uncommon adverse reaction of ACE-I/ARB therapy, occurring at rates exceeding 20%.23 Interestingly, hyperkalemia was not associated with ACE-I/ARB use in our study.